sorafenib,tremelimumab,durvalumab
astrazeneca,pfizer
['hcc', 'himalaya', 'lcsm,(-blcsm)']
#stride in patients with #uhcc showed manageable and low-grade immune-related adverse events, according to findings from the phase 3 himalaya trial presented at #asco2023. #lcsm | 
Oncology news and insights from leading researchers and cancer centers.